Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 93-96

  Zalupski, Mark M ^a,b   Shields, Anthony F ^a   Philip, Philip A ^a   Kraut, Michael ^a   LoRusso, Patricia ^a   Heilbrun, Lance K ^a   Vaitkevicius, Vainutis ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b Division of Hematology and Oncology   (United States)

Author keywords

Pancreatic cancer; Pyrazoloacridine; PZA

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; ACRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ACRIDINES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PANCREATIC NEOPLASMS; PYRAZOLES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031824186     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006087114621     Document Type: Article

References (17)

1. Adjei AA, Charron M, Rowinsky EK, Donehower RC, Sebolt-Leopold J, Kaufmann SH: Pyrazoloacridine (PA) inhibits DNA topoisomerases (topo) I and II. Proc AACR 36:349, 1995
2. Berg SL: Status of new anthrapyrazole and pyrazoloacridine derivatives. Crit Rev Oncol/Hem 22:79-87, 1995
3. Sebolt JS, Scavone SV, Pinter CD, Hamelehele KL, Van Hoff DD, Jackson RC: PZAs, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47:4299-4303, 1987
4. Sebolt J, Havlick M, Hamelehele K, Nelson J, Leopold W, Jackson R: Activity of PZA against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24:219-224, 1989
5. Jackson RC, Sebolt JS, Shillis JL, Leopold WR: The PZAs: Approaches to the development of a carcinoma-selective cytotoxic agent. Clin Invest 8:39-47, 1990
6. LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 12:1487-1493, 1995
7. Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Kathy Bowling M, Chen TL, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13:1975-1984, 1995
8. Alanen KA, Joensuu H: Long-term survival after pancreatic adenocarcinoma - often a misdiagnosis? Br J Cancer 68:1004-1005, 1993
9. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Porteney RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Van Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413, 1997
10. Oster MW, Gray R, Panasci L, Perry MC, For Cancer and Leukemia Group B: Chemotherapy for advanced pancreatic cancer: A comparison of 5-Fluorouracil, Adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 57:29-33, 1986
11. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF: A Phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 65:2207-2212, 1990
12. LoRusso P, Wozniak AJ, Polin L, Capps D, Leopold WR, Werbel LM, Biernat L, Dan ME, Corbett TH: Antitumor efficacy of PD 115934 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900-4905, 1990
13. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
14. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
15. Sack GH, Levin J, Bell WR: Trousseau's syndrome and other manifestations of chronic disseminate coagulopathy in patients with neoplasms. Medicine 56(1):1-37, 1977
16. Zalupski MM, Philip PA, LoRusso P, Shields AF: Phase II study or pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chem Pharm 40:225-227, 1997
17. Pelley RJ, Ganapathi R, Wood L, Budd GT, McLain D, Elson P, Grabowski D, Maclsaac D, Bukowski RM: Phase II trial of pyrazoloacridine (PZA) in metastatic colorectal carcinoma patients. Proc Am Soc Clin Oncol 15:220, 1996